A phase I study assessed the feasibility and safety of cellular immunotherapy using ex vivo expanded autologous memory-enriched T cells, genetically modified with a self-inactivating (SIN) lentiviral vector to express a HER2-specific, hinge-optimized, 41BB-costimulatory CAR, as well as a truncated human CD19 (HER2[EQ]BBzeta/CD19t+), for participants with recurrent/refractory malignant glioma. This evidence concerns the gene ERBB2 and malignant glioma.